In order to reflect his expectations for lower margins and higher interest costs, analyst Tom Jones has axed his earnings per share (EPS) forecast for the 2012-2016 period by between 6% and 10%.
At 1609 GMT today Rhoen-Klinikum's share lost 2.92% to EUR15.3 in floor trading on the Frankfurt Stock Exchange. The stock fell 2.57% to EUR15.28 at 1626 GMT on Xetra.
(EUR 1.0 = USD 1.308)
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government